Article info
Research paper
Assessment of industry data on pulmonary and immunosuppressive effects of IQOS
- Correspondence to Dr Farzad Moazed, Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA; farzad.moazed{at}ucsf.edu
Citation
Assessment of industry data on pulmonary and immunosuppressive effects of IQOS
Publication history
- Received February 6, 2018
- Revised July 19, 2018
- Accepted July 20, 2018
- First published August 29, 2018.
Online issue publication
October 22, 2018
Article Versions
- Previous version (29 August 2018).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.